Biotech company BioSenic (Euronext Brussels/Paris:BIOS) announced on Tuesday that it has secured a key patent from the Canadian Intellectual Property Office, enhancing protection for its arsenic trioxide (ATO) platform.

Titled 'Use of metal ions to potentiate the therapeutic effects of arsenic', the new patent encompasses the therapeutic application of ATO combined with metal ions such as copper. This combination shows promise in treating autoimmune diseases, cancer and infectious pathologies related to cytokine storms.

Similar protection was granted in Europe and Australia last year, together with a first patent acceptance in China, which opened the doors for further divisional applications in addition to the primary decision limited to graft-versus-host disease (GvHD).

The growth of BioSenic's IP portfolio aligns with its strategy to establish robust protection for its lead product, facilitating clinical and commercial advancements in autoimmunity and oncology.

Medsenic, BioSenic's subsidiary, will leverage the patent for immediate application in chronic GvHD and later in systemic sclerosis and systemic lupus erythematosus.